P25004 Pre-Assessment

Name
1. Which of the following best represents your profession?
2. What is your primary specialty?
3. What is the primary mechanism underlying ARIA related to amyloid targeting therapy?
4. A 61-year-old patient carrier of APOE ε4 who is receiving amyloid targeting therapy is being monitored for ARIA. Which MRI sequence would you use to detect for ARIA-H?
5. For a patient receiving donanemab, at what point should MRI scans be conducted?
6. A 72-year-old patient with mild cognitive impairment on amyloid targeting therapy undergoes routine MRI. FLAIR imaging reveals hyperintense cortical and subcortical regions without associated restricted diffusion. There is no evidence of infarction or mass effect. What finding do you report to the referring neurologist?
7. MRI of a patient on amyloid targeting therapy reveals FLAIR hyperintensities involving multiple lobes, each < 10 cm, without significant mass effect. What is the interpretation of the brain MRI findings?
8. The referring physician requests clarification on a radiology report in which a limited brain MRI revealed possible ARIA-E for a patient who had been experiencing a headache while on amyloid targeting therapy. What is the key patient safety consideration in this situation?
9. How confident are you in your ability to monitor ARIA among patients with Alzheimer's disease who are receiving amyloid targeting therapies?
Scroll to Top